EXPRESS SCRIPTS® CHAMPIONS FOR BETTER™

Please note that the discount information previously provided may have been incorrect. Please see below for the correct discount information.

Updates to the Specialty Drug List for April 2020

Padcev

On December 18, 2019, the FDA approved Padcev™ (enfortumab vedotin-ejfv) for the treatment of adult patients who have locally advanced or metastatic urothelial cancer that has already been treated with platinum-based chemotherapy and a programmed cell death-1 (PD-1) inhibitor or a programmed death-ligand 1 (PD-L1) inhibitor. When initially approved, Padcev was only available to hospitals; it is now available through open distribution. Given as an intravenous infusion, its recommended dosing is 1.25mg/kg on the first, eighth and fifteenth days of 28-day treatment cycles until disease progression or unacceptable toxicity. For a 70kg patient, the estimated AWP per treatment cycle is $34,185. Client discount for mail AWP is 15.00% and client discount for retail is 12.00%.

Trazimera

On March 11, 2019, the FDA approved Trazimera™ (trastuzumab-qyyp), a biosimilar to Herceptin®, however, it was recently launched. Trazimera was approved for both Herceptin-approved indications. It is indicated for treating patients with breast or metastatic stomach cancer (gastric or gastroesophageal junction adenocarcinoma) whose tumors overexpress the HER2 gene (HER2+). It is administered by intravenous infusion and is available through open distribution. The dose and cost of Trazimera varies depending on indication and patient weight. Compared to Herceptin, Trazimera is approximately 22% lower in AWP cost. Client discount for mail AWP is 15.00% and client discount for retail is 12.00%.

Drugs that will not be dispensed via Accredo:

Adakveo

On November 15, 2019, the FDA approved Adakveo ® (crizanlizumab-tmca) to reduce the frequency of vaso-occlusive crises (VOCs) in patients 16 years of age and older who have sickle cell disease. It will be available through open distribution, however, a business decision has been made not to dispense Adakveo.

Koselugo

On April 10, 2020, the FDA approved Koselugo ® (selumetinib) for the treatment of pediatric patients two years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN). Koselugo is being launched through a network of specialty pharmacies that does not include Accredo.

Pyrimethamine, authorized generic to Daraprim
On March 11, 2020, the launch of authorized generics to Daraprim ® (pyrimethamine) was announced. Pyrimethamine is indicated for treating toxoplasmosis (toxoplasma gondii) when used in combination with a sulfonamide antibiotic. Authorized generics are being launched through a network of specialty pharmacies that does not include Accredo.

Vyepti
On February 21, 2020, the FDA approved Vyepti™ (eptinezumab-jjmr) for the prevention of migraine in adults. Vyepti is being launched through a network of specialty pharmacies that does not include Accredo.

Definition of a Specialty Drug:
Specialty drugs, which can be given by any route of administration and are typically used to treat chronic, complex conditions, are defined as having one more of several key characteristics, including:

1. The requirement for frequent dosing adjustments and intensive clinical monitoring to decrease the potential for drug toxicity and increase the probability for beneficial treatment outcomes
2. The need for intensive patient training and compliance assistance to facilitate therapeutic goals
3. Limited or exclusive specialty pharmacy distribution
4. Specialized product handling and/or administration requirements

Thank you,
Express Scripts

Express Scripts
One Express Way
St. Louis, MO 63121